Genesis HealthCare (GEN) Tops Q3 EPS by 12c; Guidance Reaffirmed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Genesis HealthCare Reports Third Quarter 2016 Results
November 3, 2016 4:02 PM EDTAnnounces Planned Divestiture of Facilities in Eight States to Focus on Core Markets
Recently Announced New Leases Reduce Prior Lease Obligation by $440 Million through January 2032 Third Quarter EBITDA Meets First Call Consensus Estimate
KENNETT SQUARE, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Genesis HealthCare (Genesis, or the Company) (NYSE: GEN), one of the largest post-acute care providers in the United States, today announced operating results for the third quarter ended September 30, 2016.Â
... MoreGenmab Announces Financial Results for the First Nine Months of 2016 and Improves 2016 Financial Guidance
November 2, 2016 12:02 PM EDTNovember 2, 2016; Copenhagen, Denmark;
Interim Report for First Nine Months Ended September 30, 2016
Highlights
Net Sales of DARZALEX® (daratumumab) by Janssen for the first nine months of 2016 were USD 372 million, resulting in royalty income of USD 45 million (DKK 298 million)... More